MegaStudy Q1 2026 Net Profit Up 56% Despite Operating Profit Decline

Consolidated revenue: 27.57bn won (-4.3% YoY), operating profit: 1.53bn won (-8.1%)
Net profit attributable to parent: 4.57bn won (+56.4%), EPS: 401 won (from 256 won)
Standalone revenue: 14.68bn won (-3.5%), operating profit: 2.34bn won (+1.7%), net profit: 7.97bn won
Despite lower operating profit, net profit surged due to financial gains (valuation gains, etc.) of 4.74bn won (+3.19bn)
Borrowings: 26bn won, cash equivalents: 96.8bn won, adjusted debt ratio: 29.8% (vs 27.6% at year-end 2025)
Contingent liabilities: put options (buyback rights) related to subsidiary MegaBMC worth 28bn won
Lawsuit: MegaMD lecturer fee claim of 36m won (first trial ongoing)
Treasury shares: 513,957 shares held; no quarterly dividend